

**LABORATORY
EVALUATION
of
HEMOSTASIS**

SIRRIDGE

SECOND EDITION

LABORATORY EVALUATION OF HEMOSTASIS

Second Edition

Author:

Marjorie S. Sirridge, M.D.

*Docent and Professor,
University of Missouri—Kansas City,
School of Medicine
Hematology Consultant,
Providence-St. Margaret Health Center
Bethany Medical Center*

Lea & Febiger

1974

Philadelphia



Library of Congress Cataloging in Publication Data

Sirridge, Marjorie S.

Laboratory evaluation of hemostasis.

(Medical technology series)

1. Blood—Analysis and chemistry. 2. Hemostasis.

I. Title. II. Series.

RB145.S55 1974 616.07'561 73-10452

ISBN 0-8121-0389-0

Copyright © 1974 by Lea & Febiger. Copyright under the International Copyright Union. All rights reserved. This book is protected by copyright. *No part of it may be reproduced in any manner or by any means without written permission from the publisher.*

Published in Great Britain by
Henry Kimpton Publishers, London
Printed in the United States of America

Medical Technology Series

Other titles available:

Sidney L. Dale: Principles of Steroid Analysis

Loyd W. Hedgecock: Antimicrobial Agents

Clifton E. Meloan: Instrumental Analysis Using Physical Properties

Jean H. Priest: Cytogenetics

Martha Winstead: Instrument Check Systems

Milton W. Hamolsky: Thyroid Testing

Walter E. Haesler, Jr.: Immunohematology

S. T. Nerenberg: Electrophoretic Screening Procedures

Preface

Since the first edition of this book was published in 1967, I have continued to care for many patients with hemostatic problems, to teach many medical students and technologists about bleeding disorders, and to participate in several laboratories in the modification of some established tests and the evaluation and utilization of many new ones.

My primary interest continues to be in those studies that can be done in the routine laboratory and that relate to the diagnosis and care of patients. I appreciate the large role of the manufacturers of coagulation reagents in the progress in availability of new reagents and quality control. I have been increasingly impressed with the need for qualified medical technologists who really understand the process of hemostasis because of the many pitfalls that continue to plague the laboratory workers in this field.

Our understanding of the hemostatic process has increased greatly in the past six years, particularly with the wide recognition of the entity of disseminated intravascular coagulation and with beginning efforts to study hypercoagulability. The wide availability of factor concentrates has challenged the laboratory to develop more accurate methods for measuring levels of coagulation factors. New methods for the study of platelet function have added greatly to our understanding of some of the milder hemorrhagic syndromes.

Every year I see at least one patient with a combination of findings and

problems that I have not seen before, so I anticipate a future filled with continuing advancement and challenge.

A major effort has been made in this edition to standardize procedures and reagents, so that a laboratory can do complete and careful work with a minimum of equipment and reagents. This should be of particular importance to beginning technologists. Readily available reagents have been utilized whenever possible, and information about availability, stability, and sensitivity has been included.

I wish to thank Dr. James Davis for so adequately describing the study of platelet aggregation. His many years of careful study of platelets make him eminently qualified for this task. I also wish to thank Reaner Shannon and Henry Revels who have worked so diligently on the actual testing done in our coagulation laboratory and who have helped with the development and description of many procedures that appear in this book.

I am indebted to Dr. Larry Tretbar, Betty Steinmann, and the Audio-Visual Department of the UMKC School of Medicine for their invaluable help in the development of the new illustrations for this edition. Also for long hours of typing and proofreading, I wish to thank Sue Hodes, Verdis Moore, and Joan Rice.

MARJORIE S. SIRRIDGE
Kansas City, Missouri

Contents

1	Mechanism of Hemostasis	2
	Blood Vessels	4
	Platelets	5
	Coagulation System	5
	International Nomenclature of Coagulation Factors	6
	Stages of Coagulation	8
	Kinetics of Coagulation	16
	Inhibitors of Coagulation	17
	Inhibitors of Thrombin	17
	Heparin and Heparin-like Substances	18
	Inhibitors of the Plasminogen-Plasmin System	19
2	Disorders of Hemostasis	20
	Vascular Disorders	20
	Vascular Purpura	21
	Congenital Telangiectasia	22
	Connective Tissue Dysplasias	22
	“Easy Bruisability”	23
	Increased Vascular Fragility	23
	Anaphylactoid Purpura	23
	Drug Toxicity	24

Senile or Steroid Purpura	24
Purpura Associated with Systemic Disease	24
Purpura of Increased Intracapillary Pressure	25
Platelet Abnormalities	25
Thrombocytopenia	26
Thrombocytosis	27
Defects of Platelet Adhesiveness	28
Thrombasthenia	30
Thrombocytopathy	31
Coagulation Syndromes	32
Congenital Deficiencies of Factors VIII and IX (Hemophilia)	33
Congenital Deficiencies of Factors I, II, V, VII, X, XI, XII, or XIII	35
Combined Congenital Deficiencies	40
Combined Acquired Deficiencies of the Vitamin K-dependent Factors	40
Acquired Circulating Coagulation Inhibitors	41
Stage I Anticoagulants	42
Middle Stage Anticoagulants	43
Anticoagulants Related to Fibrin Formation	43

	Anticoagulant Therapy	44
	Intravascular Coagulation and Fibrinolysis	47
	Hemorrhagic Disorders Associated with Common Systemic Diseases	52
	Hypercoagulability and Thromboembolism	53
3	General Principles of Testing	65
	Collection of Blood	56
	Capillary Blood	56
	Venous Blood	58
	Temperature	58
	Influence of Time	58
	End Point	59
	Deficiency versus Inhibitor	59
	Types of Tests	60
	Screening Tests	60
	Follow-up Testing	60
	Recommended Testing Procedure in Suspected Disseminated Intravascular Clotting (DIC)	63
	Relationship of Tests to Hemostatic Mechanism	64
4	Evaluation of the Vascular Factor	68
	General Principles	68
	Tourniquet Test	70
	Bleeding Time (Ivy Method)	70
	Modification of Ivy Bleeding Time (Borchgrevink)	71
	Aspirin Tolerance Test	73
5	Evaluation of Platelets	74
	General Principles	74
	Examination of Blood Smear for Platelet Numbers and Morphology	76
	Platelet Count	77
	Measurement of Platelet Adhesiveness	77
	In Vivo Methods	77
	In Vitro Glass Bead Adhesiveness	78
	Observation of the Clot	81
	Platelet Aggregation	83
	Platelet Factor 3 Availability Test	89
6	Evaluation of Overall Tests of Coagulation	92
	Whole Blood Clotting Tests	92
	Whole Blood Clotting Time	93

	Ground Glass Clotting Time	94
	Whole Blood Activated Partial Thromboplastin Time	95
	Plasma Recalcification Tests	95
	Problems in the Use and Interpretation of PTT and APTT Tests	100
	Partial Thromboplastin Time	102
	Activated Partial Thromboplastin Time	104
	Activated Partial Thromboplastin Time of Diluted Plasma	105
	Differential Activated Partial Thromboplastin Time	106
7	Evaluation of Stage I	108
	General Principles	108
	Prothrombin Consumption Test	110
	Standard Thromboplastin Generation Test (TGT)	114
	Whole Blood Screening Thromboplastin Generation Test (Screening TGT)	120
	Modification for Capillary Blood	122
	Correction Studies for Abnormal Whole Blood Screening TGT	123
	Hicks-Pitney Test	124
	One-stage Assay Method for Factors VIII, IX, XI, and XII ...	126
	Two-stage Assay for Factor VIII	131
8	Evaluation of Stages II and III	136
	General Principles	136
	Prothombin Time	138
	Correction Studies for a Prolonged Prothrombin Time	142
	Stypven (Russell's Viper Venom) Time	143
	Prothrombin-Proconvertin Test	144
	Thrombotest	145
	Sample Assay Method for Prothrombin Factors (II, V, VII, and X)	145
	Preparation of a Dilution Curve	146
	Evaluation of Stage III.....	148
	Measurement of Fibrinogen	148
	Detection of Structural Abnormalities in Fibrinogen	149
	Detection of Inhibitors of Thrombin	149
	Detection of Factor XIII Activity	150
	Thrombin Time	150
	Preparation of a Heparin Control Curve	151
	Fibrinogen Assay (Clauss)	154
	Semiquantitative Plasma Fibrinogen Determination (A Rapid Titration Method)	155

	Fibrinogen Assay (Folin-Ciocalteu Method)	156
	Qualitative Test for Fibrin Stabilizing Factor (Clot Stability in 5 Molar Urea)	158
9	Evaluation of Stage IV (Fibrinolysis)	160
	Tests for Clot Lysis	160
	Tests for the Presence in Serum of Fibrin-Fibrinogen Degradation Products	164
	Whole Blood Clot Lysis	166
	Observation of Whole Blood Clot for Retraction and Lysis	167
	Indirect Plasma Clot Lysis	167
	Plasma Fibrinogen Determination and Diluted Plasma Clot Lysis (A Rapid Titration Method)	168
	Diluted Whole Blood Clot Fibrinolysis	170
	Euglobulin Lysis Time	171
	Staphylococcal Clumping Test	172
10	Tests Useful in the Diagnoses of Intravascular Clotting and Hypercoagulability	176
	Serial Dilution Protamine Sulfate Test	179
	Ethanol Gelation Test	180
	Cryofibrinogen	180
	Antithrombin III	181
11	Detection of Circulating Coagulation Inhibitors	184
	Screening Test for a Coagulation Inhibitor	186
	Assays for Inhibitors of Factors VIII and IX	188
	Protamine Sulfate Titration for Heparin Activity	188
	Appendix	190
	I. Equipment	190
	II. Reagents	192
	Index	204

Medical Technology

1

Mechanism of Hemostasis

Blood is normally fluid; in the body it circulates throughout the vascular system under pressure. The prevention of spontaneous bleeding and the control of traumatic hemorrhage are referred to as hemostasis—a complex mechanism which is dependent primarily upon:

1. Normal resistance and contractility of blood vessels and an adequate supportive framework for them.
2. Normal platelet activity.
3. An adequate coagulation system.
4. Stability of the clot.

In the prevention of spontaneous bleeding, the normality of the vascular system and the presence of adequate numbers of normally functioning platelets are of primary importance. It seems likely that bleeding due to minute traumatic stresses and injuries to small blood vessels is regularly controlled by the adherence of small numbers of platelets to injured areas. Perhaps the best indication of the effectiveness of such a protective mechanism is the rare occurrence of petechiae when the tourniquet test is performed on normal individuals. The mechanism is not sufficient, however, if there is an abnormality in the vessels themselves or if platelets are reduced in number or do not function normally. With increased vascular fragility, apparently even

normal platelets are inadequate, and in thrombocytopenia, normal vessels alone cannot prevent the appearance of petechial bleeding.

Vessels, platelets, the coagulation system, and clot stability are all important in hemorrhage control. The exact sequence of events is variable. Eventually, the openings in bleeding vessels must be closed so that the blood can no longer escape, and, except in very small venules and capillaries, this is usually accomplished by the formation of clots within the lumens of the vessels. The following factors are of variable importance in determining the pattern of hemostasis:

1. Location of the injured vessels and the chance of continuing trauma to them.
2. Size of the vessels and blood pressure within them.
3. Intrinsic abnormalities in the vessels.
4. Damage to surrounding tissue.
5. Accumulation of blood in tissues surrounding the vessels.
6. Application of external pressure or surgical intervention.

With large arterial vessels in which the blood pressure is high, usually there is no way for the flow of blood to be slowed sufficiently to allow clotting without the application of a tourniquet, the use of external pressure at the

bleeding site, or some type of surgical intervention. Occasionally there is enough tissue damage surrounding the vessel, with accumulation of blood in this tissue, to produce local tamponade of an artery and eventual cessation of bleeding. With repeated trauma, however, bleeding may be easily reactivated. In small venules and capillaries, hemostasis may be accomplished by the simple adhesion of endothelial surfaces and the local aggregation of platelets. In small arteries and arterioles, spontaneous control of bleeding is possible by a rather complex mechanism which is outlined in Figure 1-1.




Figure 1-1. Hemostasis in small arteries and arterioles.

A more complete stepwise progression of changes occurring soon after injury to the wall of the blood vessel includes the following events and processes:

1. Adherence of platelets to the injured vessel wall and release of ADP, which occurs within 3 seconds, simultaneously with the beginning of activation of prothrombin to thrombin by tissue factor that was released by injury.
2. Formation of platelet aggregates with small fibrin loci within 30 seconds.
3. Disintegration of platelets and expansion of fibrin loci beginning in 1 minute.
4. Disintegration of platelet membranes and confluence of fibrin loci and platelet aggregates by 4 minutes.

BLOOD VESSELS

When blood vessels are normal, blood cells are retained within them except when actual injury occurs. However, defects in structure, permeability,

MECHANISM OF HEMOSTASIS

contractility, and resistance to trauma may interfere with adequate hemostasis. The recognition of such defects rests primarily on careful clinical observation rather than upon laboratory studies. Clinical evaluation is made not only upon observation of the bleeding area, but also upon inspection of the surrounding tissues and the remainder of the patient's body for evidence of generalized disease that might affect vascular function. The only laboratory procedures which aid in this problem are the tourniquet test and the determination of the bleeding time.

PLATELETS

Platelets have a variety of functions and, because of these, can be studied and tested in a number of ways. They aid in the maintenance of normal vascular integrity and plug holes in small vessels. They adhere to damaged vessels and aggregate at the sites of trauma, causing the slowing of blood flow, the prolonged constriction of surrounding vessels, and the actual beginning of clot formation. A number of separate platelet factors have been described. Platelet factor 1 is nothing more than adsorbed plasma factor V. Platelet factor 2 is located inside the platelet and accelerates the conversion of fibrinogen to fibrin. Platelet factor 3 is the lipoprotein which is necessary for the intrinsic formation of prothrombin converting complex. Platelet factor 4 neutralizes heparin. Fibrinogen seems to be partially adsorbed from plasma and partially located inside platelets. It has also been suggested that factor XIII is derived from platelets. Platelets are active in coagulation only after these factors are released.

Platelets may be counted directly, or their numbers may be estimated on blood smears. Estimation is much easier than actual counting because of the very small size of the platelets and is sufficiently accurate for the study of most hemostatic diseases, since numbers must be greatly altered (probably below 50,000 or over 1,000,000) to cause significant bleeding problems. In some situations, however, when rapid changes are occurring in platelet levels, it may be important to have sequential counts. Two such situations are the consumption coagulopathy associated with disseminated intravascular clotting and the patient with acute thrombocytopenic purpura. Estimation of the number of platelets on a stained smear is helpful also because it allows for observation of platelet morphology. Platelet function tests include the tourniquet test, the bleeding time, the prothrombin consumption test, the standard thromboplastin generation test, clot retraction, platelet adhesiveness, platelet aggregation, and the platelet factor 3 availability test.

COAGULATION SYSTEM

The coagulation system is by far the most complex part of the hemostatic mechanism and involves the interaction of ten or more different factors in

plasma and tissue, as well as the regulation of these factors by natural inhibitors. Our present concepts of the workings of the system are the result of some simple observations and the studies of many investigators. Some basic facts which are important in the understanding of coagulation include:

1. In a glass tube, blood clots in about 10 minutes.
2. In a plastic or siliconized tube, blood may take as long as 30 minutes to clot.
3. In a plastic or siliconized tube, if powdered glass or other activating substances are added, blood will clot in about 2 minutes.
4. Blood to which tissue extract has been added clots in a few seconds.
5. The clotting time of plasma is much shorter than that of whole blood and shows a variability which is at least partially dependent upon the speed and time of centrifugation.
6. The clotting time of plasma may be reduced by adding a platelet substitute, an activator substance, or tissue extract.

From the above and similar observations, the following conclusions can be drawn:

1. Blood contains all factors needed to form a clot.
2. Some factor or factors in blood must be activated by contact with a glass tube, and this appears to be a time-consuming process. Activation is less in plastic and siliconized tubes than in glass tubes.
3. The process of contact activation could not require calcium, since there is at least partial activation in blood or plasma to which a calcium-binding anticoagulant has been added.
4. Tissue factor contains a substance or substances that bypass contact activation.
5. Since platelets influence the speed of the clotting process to some extent, they must also be involved in the intrinsic coagulation system.

International Nomenclature of Coagulation Factors

An international nomenclature has been established for the coagulation factors. This should be mastered before trying to follow the discussion of the probable manner in which these factors interact. It is easier to refer to all factors by number, except for fibrinogen (I), prothrombin (II), thromboplastin (III), and calcium (IV) which, because of their key positions in the clotting mechanism and their early description, are regularly referred to by name. Table 1-1 designates the factors by number and by the various names used to refer to them and also includes some of the known facts that are important in studying and understanding them.